ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves First Biosimilar for Non-Hodgkin’s Lymphoma
americanpharmaceuticalreview
November 29, 2018The U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive..... -
Poteligeo approved in Europe for Mycosis Fungoides, Sézary Syndrome
pharmatimes
November 27, 2018Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome, the two most common subtypes of cutaneous T-cell lymphoma, a rare type of non-Hodgkin’s lymphoma.
Pharma Sources Insight January 2025
